Published on 22/12/2025
Complying with ICMJE Guidelines on Clinical Trial Data Sharing Statements
Introduction: The Growing Importance of Data Sharing in Clinical Trials
In an era emphasizing transparency and reproducibility, data sharing has become a key ethical and regulatory expectation in clinical research. As part of this global movement, the International Committee of Medical Journal Editors (ICMJE) introduced mandatory data sharing statements for clinical trial manuscripts submitted on or after July 1, 2018.
This requirement applies to all interventional clinical trials involving human participants. The purpose is to inform readers, participants, and regulators whether the authors intend to share individual participant data (IPD), under what conditions, and through which mechanisms. This article offers a comprehensive guide to crafting ICMJE-compliant data sharing statements.
ICMJE Data Sharing Policy Overview
The ICMJE’s 2017 data sharing policy outlines the need for a clearly articulated data sharing plan at the time of trial registration, and a detailed statement at the time of publication. While data sharing is not mandated, transparency about intent is required. Specifically, authors must disclose:
- Whether they will share IPD
- What specific data will be shared (e.g., de-identified participant data, statistical analysis plans)
- When the data will become available and for how long
- By
These requirements apply to trial manuscripts submitted to ICMJE-member journals and others that follow their editorial standards.
When and Where to Include the Data Sharing Statement
Authors are expected to register their data sharing plan in the trial registry (e.g., ClinicalTrials.gov, EU Clinical Trials Register) prior to patient enrollment. At the time of publication, the final data sharing statement must be included in the manuscript, often at the end of the “Methods” section or under a standalone “Data Sharing” heading.
ICMJE member journals, including The BMJ, The Lancet, and NEJM, have incorporated this requirement into their editorial workflows and will reject manuscripts that lack compliant disclosures.
Examples of ICMJE-Compliant Data Sharing Statements
To help authors, ICMJE offers sample formats. Examples include:
- “De-identified individual participant data (IPD) will be made available, including data dictionaries, beginning 3 months after publication and ending 5 years following article publication. Data will be accessible through request to the corresponding author.”
- “No IPD will be shared. The trial data is proprietary and part of a product development program.”
- “Only statistical analysis plans and protocol will be available upon request for researchers with an approved proposal.”
The key is clarity, specificity, and consistency between trial registry and publication.
Ethical Considerations in Data Sharing
While transparency is the goal, patient privacy and consent are non-negotiable. Ethical concerns include:
- Informed consent: Participants should be informed about potential future data sharing during enrollment.
- Anonymization: All shared data must be de-identified to prevent re-identification risk, especially in rare disease populations.
- Use limitations: Secondary use should align with ethical approval and not harm participants.
For global trials, sponsors must also consider compliance with jurisdictional laws like GDPR, HIPAA, and country-specific data protection acts.
Repositories and Platforms for Data Sharing
Data sharing must be feasible and secure. Authors can use a variety of established repositories depending on their region and data type:
- ClinicalStudyDataRequest.com (multi-sponsor)
- Vivli (global data sharing platform)
- YODA Project (Yale)
- Dryad, Zenodo, or institutional repositories for supplementary data files
Most repositories require submission of data use agreements and review of proposed research plans before granting access.
Data Sharing Plans and Trial Registration
When registering trials, sponsors must complete the data sharing section in registries like ClinicalTrials.gov. Required fields typically include:
- Plan to share IPD (Yes/No/Undecided)
- Description of data to be shared
- Additional documents to be shared (e.g., protocols, SAPs)
- Timeframe and access method
Consistency between registration, informed consent, and final publication is essential to ensure transparency and avoid post-approval scrutiny.
Data Sharing and ICMJE Journal Acceptance
Many ICMJE-compliant journals now reject trial manuscripts lacking proper data sharing disclosures. To improve acceptance odds, trial authors should:
- Align registry and manuscript disclosures
- Provide repository access links, if data are already available
- Mention any embargo or proprietary restrictions upfront
Journals such as BMJ Open, Trials (BMC), and PLOS ONE provide guidance on IPD sharing formats and encourage proactive archiving at submission stage.
Managing Risk in Data Reuse and Interpretation
One concern raised by sponsors is the misuse or misinterpretation of shared data. Strategies to manage this include:
- Using controlled access repositories
- Requiring data use agreements and approved protocols
- Requesting co-authorship or collaboration when appropriate
However, ethical guidelines generally discourage placing unnecessary restrictions on legitimate scientific inquiry using shared data.
Conclusion: Transparency Through Data Sharing
The ICMJE data sharing requirement is a landmark step toward greater transparency in clinical research. While not all trials may share IPD, all must clearly communicate their intent and access policies. By aligning ethical, legal, and publication responsibilities, trial sponsors and authors can fulfill both regulatory mandates and the public trust.
Planning data sharing from the protocol stage, obtaining proper consent, and ensuring robust data governance are essential to making this transparency sustainable and impactful.